Peptide Composition for Cartilage Formation via COX-2 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bone defects and osteoarthritis lack effective methods for promoting bone and cartilage regeneration, with existing therapies primarily focusing on pain management and temporary repair, while there is a need for therapies that can stimulate specific bone growth without ectopic ossification and promote cartilage repair.
Innovation Solution
A peptide compound with a specific amino acid sequence motif, such as DLXXXNDXXPFXXXXQXF, is used in combination with a pharmaceutically acceptable carrier for controlled release, stimulating growth of hard tissues like bone and cartilage, and activating COX-2 for cartilage formation, as demonstrated in goat models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If BMP molecules are used to stimulate new bone formation, then bone formation activity is improved, but ectopic ossification occurs in soft tissues
Solution Approach 1:
The invention extracts and utilizes only the N-terminal fragment (residues 1-50) of the BMP-2 molecule, which contains the essential bone-forming activity while removing the C-terminal region responsible for non-selective bone formation and ectopic ossification. This fragmented approach preserves therapeutic benefit while eliminating harmful side effects.
Solution Approach 2:
The BMP-2(1-50) fragment exhibits localized and selective bone formation activity specifically at the implant site when combined with a biodegradable carrier, rather than causing widespread ectopic ossification. The carrier material confines the biological activity to the intended location, providing spatial control over the therapeutic effect.
2Productivity
If BMP molecules are administered systemically, then bone formation is stimulated, but selectivity to bone tissue is lost
Solution Approach 1:
A biodegradable carrier material serves as an intermediary between the BMP-2(1-50) fragment and the target bone tissue. The carrier provides controlled local delivery, ensuring the peptide reaches and acts specifically on bone tissue at the implant site while preventing systemic distribution and maintaining high tissue selectivity.
3Object-affected harmful factors
If carrier material is used for localized BMP delivery, then ectopic ossification is prevented, but device complexity increases
Solution Approach 1:
The invention changes the molecular parameters of the BMP molecule by using a truncated fragment (1-50 residues) instead of the full-length protein. This parameter change allows the peptide to maintain bone-forming activity while requiring simpler carrier materials, as the smaller fragment has reduced potential for off-target effects and can be delivered through less complex delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide compound effectively promotes cartilage and bone formation, showing dose-dependent regeneration in osteoarthritis models, potentially offering a more sustainable repair solution beyond current pain management approaches.
Implementation Method 1
AC-100 has also shown bone formation activities in vivo... demonstrated to stimulate proliferation, differentiation, and mineralization of human osteoblastic cells
Implementation Method 2
stimulate proliferation, differentiation, and mineralization of human osteoblastic cells
Implementation Method 3
stimulate proliferation, differentiation, and mineralization of human osteoblastic cells
Implementation Method 4
activating COX-2 for cartilage formation
Implementation Method 5
promote cartilage repair... effectively promotes cartilage and bone formation, showing dose-dependent regeneration in osteoarthritis models
Implementation Method 6
A peptide compound with a specific amino acid sequence motif, such as DLXXXNDXXPFXXXXQXF, is used in combination with a pharmaceutically acceptable carrier for controlled release
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is a peptide compound which stimulates the formation of hard tissues such as bone and cartilage. The invention is also related to a method to treat a defect in hard tissues such as bone and cartilage using the peptide. The method of the present invention may be used to treat or prevent the defects in bones and cartilages which are caused by rheumatoid arthritis or osteoarthritis which involves the regeneration of new bone or cartilage in or around the defects.